WANY
BBIO icon

Wealthspire Advisors (New York)’s BridgeBio Pharma BBIO Stock Holding History

Wealthspire Advisors (New York)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-125
Closed -$6.49K – 1214
2025
Q3 		$6.49K Buy
+125
New +$6.1K ﹤0.01% 2227

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthspire Advisors (New York)'s BBIO Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 125 shares — an estimated $6.49K sold.

Wealthspire Advisors (New York) first reported a position in BBIO in Q3 2025 and held it in 1 quarter. The position peaked at $6.49K in Q3 2025. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 125 BridgeBio Pharma shares in Q4 2025, an estimated $6.49K.
  • Wealthspire Advisors (New York) first reported a position in BridgeBio Pharma in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s BridgeBio Pharma position peaked at $6.49K in Q3 2025.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.